Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death
- Authors
- Maiti, K; Oh, DY; Moon, JS; Acharjee, S; Li, JH; Bai, DG; Park, HS; Lee, K; Lee, YC; Jung, NC; Kim, K; Vaudry, H; Kwon, HB; Seong, JY
- Issue Date
- Jul-2005
- Publisher
- ENDOCRINE SOC
- Citation
- JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.90, no.7, pp 4287 - 4298
- Pages
- 12
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Volume
- 90
- Number
- 7
- Start Page
- 4287
- End Page
- 4298
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/19626
- DOI
- 10.1210/jc.2004-1894
- ISSN
- 0021-972X
1945-7197
- Abstract
- Context: GnRH is known to directly regulate prostate cancer cell proliferation, but the precise mechanism of action of the peptide is still under investigation. Objective: This study demonstrates differential effects of GnRH-I and GnRH-II on androgen-independent human prostate cancer cells. Results: Both GnRH-I and GnRH-II increased the intracellular Ca2+ concentration ([Ca2+](i)) either through Ca2+ influx from external Ca2+ source or via mobilization of Ca2+ from internal Ca2+ stores. Interestingly, the [Ca2+] i increase was mediated by activation of the ryanodine receptor but not the inositol trisphosphate receptor. Trptorelix-1, a novel GnRH-II antagonist but not cetrorelix, a classical GnRH-I antagonist, completely inhibited the GnRH-II-induced [Ca2+](i) increase. Concurrently at high concentrations, trptorelix-1 and cetrorelix inhibited GnRH-I-induced [Ca2+](i) increase, whereas at low concentrations they exerted an agonistic action, inducing Ca2+ influx. High concentrations of trptorelix-1 but not cetrorelix-induced prostate cancer cell death, probably through an apoptotic process. Using photoaffinity labeling with I-125-[azidobenzoyl-D-Lys(6)] GnRH-II, we observed that an 80-kDa protein specifically bound to GnRH-II. Conclusions: This study suggests the existence of a novel GnRH-II binding protein, in addition to a conventional GnRH-I receptor, in prostate cancer cells. These data may facilitate the development of innovatory therapeutic drugs for the treatment of prostate cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 3. Graduate School > Biomedical Research Center > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.